Eteplirsen approved in US for Duchenne muscular dystrophy

The first drug to treat the underlying cause of Duchenne muscular dystrophy, Exondys (eteplirsen) developed by Sarepta Therapeutics, has secured marketing approval from the U.S. Food and Drug Administration. Duchenne muscular dystrophy is a severe type of muscular dystrophy which generally begins around age four in boys and progresses rapidly.

www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm

Prime GlobalEteplirsen approved in US for Duchenne muscular dystrophy
Share this post

Join the conversation